DELCANCER

The role of loss-of-heterozygosity in cancer development and progression

 Coordinatore VIB 

Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.

 Nazionalità Coordinatore Belgium [BE]
 Totale costo 1˙498˙764 €
 EC contributo 1˙498˙764 €
 Programma FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call ERC-2012-StG_20111109
 Funding Scheme ERC-SG
 Anno di inizio 2012
 Periodo (anno-mese-giorno) 2012-10-01   -   2017-09-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    VIB

 Organization address address: Rijvisschestraat 120
city: ZWIJNAARDE - GENT
postcode: 9052

contact info
Titolo: Dr.
Nome: Anna
Cognome: Sablina
Email: send email
Telefono: 3216330790
Fax: 3216330145

BE (ZWIJNAARDE - GENT) hostInstitution 1˙498˙764.00
2    VIB

 Organization address address: Rijvisschestraat 120
city: ZWIJNAARDE - GENT
postcode: 9052

contact info
Titolo: Mr.
Nome: Rik
Cognome: Audenaert
Email: send email
Telefono: 3292446611
Fax: 3292446610

BE (ZWIJNAARDE - GENT) hostInstitution 1˙498˙764.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

genetic    plan    loss    deletions    genes    cell    phenotypes    primary    regions    loh    regulatory    cancer    mechanisms    chromosomal    transformation    human    cells    alterations   

 Obiettivo del progetto (Objective)

'Somatically acquired loss-of-heterozygosity (LOH) is extremely common in cancer; deletions of recessive cancer genes, miRNAs, and regulatory elements, can confer selective growth advantage, whereas deletions over fragile sites are thought to reflect an increased local rate of DNA breakage. However, most LOHs in cancer genomes remain unexplained. Here we plan to combine a TALEN technology and the experimental models of cell transformation derived from primary human cells to delete specific chromosomal regions that are frequently lost in cancer samples. The development of novel strategies to introduce large chromosomal rearrangements into the genome of primary human cells will offer new perspectives for studying gene function, for elucidating chromosomal organisation, and for increasing our understanding of the molecular mechanisms and pathways underlying cancer development.Using this technology to genetically engineer cells that model cancer-associated genetic alterations, we will identify LOH regions critical for the development and progression of human cancers, and will investigate the cooperative effect of loss of genes, non-coding RNAs, and regulatory elements located within the deleted regions on cancer-associated phenotypes. We will assess how disruption of the three-dimensional chromosomal network in cells with specific chromosomal deletions contributes to cell transformation. Isogenic cell lines harbouring targeted chromosomal alterations will also serve us as a platform to identify compounds with specificity for particular genetic abnormalities. As a next step, we plan to unravel the mechanisms by which particular homozygous deletions contribute to cancer-associated phenotypes. If successful, the results of these studies will represent an important step towards understanding oncogenesis, and could yield new diagnostic and prognostic markers as well as identify potential therapeutic targets.'

Altri progetti dello stesso programma (FP7-IDEAS-ERC)

COSMIWAY (2011)

From the Milky Way to the cosmic large-scale structure

Read More  

MULTIAX (2014)

MULTIAX: Multiaxial and Multiscale Plasticity in Metals

Read More  

IN-BRAIN (2013)

IN VIVO REPROGRAMMING: A NOVEL ROUTE TO BRAIN REPAIR

Read More